Flavia Geraldes
Latest contributions
Major Late-Breaking Trials from EuroPCR 2026
20 May 2026 – From EuroPCR 2026
This session presents major late-breaking trials from EuroPCR 2026, reviewing contemporary evidence on coronary revascularization in TAVI patients, long-term outcomes of PCI versus CABG for left main disease, and comparative effectiveness of LAA closure versus NOAC in atrial fibrillation across age groups, with clinical practice implications.
Rethinking coronary artery disease: from ischaemia to atheroma - Implications of the Lancet Commission for Interventional Cardiology
20 May 2026 – From EuroPCR 2026
This session invites a re-evaluation of coronary artery disease by shifting focus from ischemia to atheroma, integrating insights from the Lancet Commission for Interventional Cardiology. It explores the significance of plaque burden, biology, and inflammation in guiding PCI decisions and outlines the future role of PCI...
Late-Breaking Trials in transcatheter mitral, tricuspid and aortic interventions - Part 1
16 Nov 2025 – From PCR London Valves 2025
This session presents pivotal late-breaking trials in transcatheter mitral and aortic valve interventions. Explore one-year outcomes from the AltaValve early feasibility study featuring atrial fixation TMVR, interim results from the TARGET study assessing Cardiovalve for tricuspid regurgitation, five-year data on transapical TMVR, and outcomes of TAVI...
